This article is more than 5 years old. Information may no longer be current.

AMO gets FDA approval for new OVD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Food and Drug Administration has granted approval to Abbott Medical Optics for Healon EndoCoat OVD, according to a press release.

Healon EndoCoat OVD offers a smaller delivery device and improved ergonomics for smooth, consistent delivery into the eye, according to the release.

“A dispersive OVD is highly desirable at the beginning of the cataract removal process to help protect the eye from nuclear particles and ultrasonic energy,” Roger F. Steinert, MD, OSN Cornea/External Disease Board Member, said in the release. “Healon EndoCoat OVD is ideal for this

protective barrier. It has outstanding clarity and does not require refrigeration, which reduces surgicenter storage costs and improves ease of use compared to a cold syringe.”

The new member of AMO’s Healon line of ophthalmic viscosurgical devices will begin shipping immediately in the United States. It can be used in combination with all other Healon products.

The device is also available in Europe, Canada and New Zealand.